Fra-1 Expression in Malignant and Benign Thyroid Tumor
Authors:
- Jeong Heon OhJOJeong Heon Oh
- Nan Hee KimNKNan Hee Kim
- Kyung Muk ChoiKCKyung Muk Choi
- Sang Jin KimSKSang Jin Kim
- Sei Hyun BaikSBSei Hyun Baik
- Dong Seop ChoiDCDong Seop Choi
Open Access
- 30 June 2001
- journal article
- research article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 16 (2) , 93-97
Abstract
The differential diagnosis of thyroid nodules is very important in deciding the treatment modality and the fine needle aspiration is the best diagnostic method. But, there are some limitations in use because of inadequate test materials and difficulty in interpreting. According to the study of oncogene and tumor suppressor gene about the origin of thyroid tumor, expression of Fra-1, one of AP-1 complex, is increased in thyroid neoplasm, though not present in the normal tissue. So, there is a possibility that it will be used as a method for the differential diagnosis of thyroid nodules. We tried to know whether presence or absence of Fra-1 expression can be used as a diagnostic method in differential diagnosis of thyroid nodules using the immunohistochemical (IHC) staining method. In 4 types of thyroid tumor that were confirmed by histologic diagnosis after operation (18 cases of adenomatous goiter, 16 cases of follicular adenoma, 30 cases of papillary cancer, 10 cases of follicular cancer), IHC staining method was performed to evaluate the expression of Fra-1. In papillary and follicular thyroid cancers, the expression of Fra-1 was stronger than in benign thyroid tumor, but there was no difference in Fra-1 expression between the two types of carcinoma. Weak expression of Fra-1 was observed in all cases of follicular adenoma, though it was weaker than in carcinoma, and it was also weakly expressed only in some cases (33%) of adenomatous goiter. The expression of Fra-1 was stronger in thyroid cancer than in benign thyroid tumor, but it was impossible to differentiate thyroid cancer from benign thyroid tumor by presence or absence of Fra-1 expression using IHC staining method.Keywords
This publication has 29 references indexed in Scilit:
- Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivoOncogene, 1998
- Neoplastic transformation of rat thyroid cells requires the junB and fra‐1 gene induction which is dependent on the HMGI‐C gene productThe EMBO Journal, 1997
- AP-1 function and regulationCurrent Opinion in Cell Biology, 1997
- Transformation by ras modifies AP1 composition and activityOncogene, 1997
- Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by rasCell, 1994
- Transformation by FosB requires a trans-activation domain missing in FosB2 that can be substituted by heterologous activation domains.Genes & Development, 1992
- The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformationBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1991
- Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers.Journal of Clinical Investigation, 1991
- Fine Needle Aspiration Biopsy in the Management of Thyroid NodulesThe Endocrinologist, 1991
- c-fos protein can induce cellular transformation: A novel mechanism of activation of a cellular oncogeneCell, 1984